Your session is about to expire
← Back to Search
Lurbinectedin + Doxorubicin for Leiomyosarcoma
Study Summary
This trial will test if a combo of two chemo drugs can prolong progression-free survival in those with metastatic leiomyosarcoma.
Eligibility Criteria
Inclusion Criteria
You will be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Awards & Highlights
Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the current total of participants in this research project?
"Affirmative. According to clinicaltrials.gov, this research is actively looking for participants and was first advertised on October 15th 2023 with the latest update being made a day later. The study demands 240 patients from only 1 location."
Are there any opportunities to volunteer for this clinical trial?
"That is correct. According to the information provided on clinicaltrials.gov, this medical research project began recruiting participants as of October 15th 2023 and was recently revised on October 16th 2023. The team are currently seeking 240 individuals from a single site for participation in their study."
Share this study with friends
Copy Link
Messenger